Validity, reliability and cut-offs of the Patient Health Questionnaire-9 as a screening tool for depression among patients living with epilepsy in Rwanda

PHQ-9 was translated to Kinyarwanda using translation-back translation and validated by a discussion group. For validation, PwE of [greater than or equal to]15 years of age were administered the PHQ-9 and Hamilton Depression Rating Scale (HDRS) by trained psychiatry staff at Visit 1. A random sample...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 15; no. 6; p. e0234095
Main Authors Sebera, Fidèle, Vissoci, Joao Ricardo Nickenig, Umwiringirwa, Josiane, Teuwen, Dirk E, Boon, Paul E, Dedeken, Peter
Format Journal Article
LanguageEnglish
Published San Francisco Public Library of Science 12.06.2020
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:PHQ-9 was translated to Kinyarwanda using translation-back translation and validated by a discussion group. For validation, PwE of [greater than or equal to]15 years of age were administered the PHQ-9 and Hamilton Depression Rating Scale (HDRS) by trained psychiatry staff at Visit 1. A random sample of 20% repeated PHQ-9 and HDRS after 14 days to assess temporal stability and intra-rater reliability. Internal structure, reliability and external validity were assessed using confirmatory factor analysis, reliability coefficients and HDRS-correlation, respectively. Maximal Youden's index was considered for cut-offs. Four hundred and thirty-four PwE, mean age 30.5 years (SD ±13.3), were included of whom 33.6%, 37.9%, 13.4%, and 15.1% had no, mild, moderate and severe depression, respectively. PHQ-9 performed well on a one-factor model (unidimensional model), with factor loadings of 0.63-0.86. Reliability coefficients above 0.80 indicated strong internal consistency. Good temporal stability was observed (0.79 [95% CI: 0.68-0.87]). A strong correlation (R = 0.66, p = 0.01) between PHQ-9 and HDRS summed scores demonstrated robust external validity. The optimal cut-off for the PHQ-9 was similar ([greater than or equal to]5) for mild and moderate depression and [greater than or equal to]7 for severe depression. PHQ-9 validation in Kinyarwanda creates the capacity to screen PwE in Rwanda at scores of [greater than or equal to]5 for mild or moderate and [greater than or equal to]7 for severe depression. The availability of validated tools for screening and diagnosis for depression is a forward step for holistic care in a resource-limited environment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: PD has received consultancy fees from UCB Pharma and Novartis. DET is an employee of UCB Pharma. PEB has received speaker and consultancy fees from UCB Pharma and grants from his institution. JNRV received a consultancy fee for the statistical analysis. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Other authors have nothing to disclose.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0234095